He has said multiple times that a company with a N
Post# of 148300
Do I believe that CYDY’s valuation will jump $1 billion because NASH preclinical results are good? No, I don’t. I honestly don’t think it will move the SP at all, even if a phase 2 is started in NASH. Why? Because at this point unless it’s revenues, non-dilutive financing, or positive cancer results, CYDY is going to stay where it’s at.
Or maybe because I’ve been here for 4+ years I’m conditioned to not seeing any news move the SP and thus I’m unable to accept the possibility of positive SP change? That’s sick if it’s true. Please CYDY, change my mind!